What is IPO Grey Market Premium (GMP)?

IPO Grey Market Premium (GMP) is an unofficial, over-the-counter premium over the issue price that dealers and investors pay prior to official listing on NSE/BSE.

How is estimated IPO listing price determined?

Estimated Listing Price = Cut-off / Issue Price + Current Grey Market Premium (GMP). For example, an issue price of ₹100 with ₹40 GMP yields an estimated listing price of ₹140 (+40%).

What is Kostak rate in an IPO?

Kostak rate is the fixed profit earned by selling an IPO application before allotment, irrespective of whether the application is allotted shares or not.

What is Subject to Sauda in IPO trading?

Subject to Sauda is an informal contract where payment is made only if the seller receives share allotment in the IPO.

Is IPO Grey Market Premium (GMP) regulated by SEBI?

No. Grey Market transactions are non-exchange over-the-counter commitments and are not officially regulated or endorsed by SEBI. Investors should treat GMP as an informal sentiment indicator.

What is the current subscription status of Onyx Biotec Limited IPO?

Onyx Biotec Limited IPO has received a total subscription of 198.68 times overall.

IPO GreyPremiumLIVE

Grey Market Intelligence

Onyx Biotec Limited

ListedSME

Healthcare · NSE

Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company focused on producing sterile water for injections and offering contract manufacturing services. It operates two facilities in Solan, Himachal Pradesh, where Unit I makes up to 6.38 lakh units of sterile water injections daily, and Unit II manufactures 40,000 units of dry powder injections and 26,667 units of dry syrup per day. The company caters to both domestic and international markets and serves over 100 clients, including well-known names like Hetero Healthcare, Mankind Pharma, Sun Pharma, and Reliance Life Sciences. Onyx Biotec is ISO 9001:2015 and ISO 14001:2015 certified and employed 175 people as of July 31, 2024.

Price Band

₹58 – ₹61

Issue Size

₹29.34 Cr

Lot Size

2000 shares

GMP

₹5

+8.2%

Est. Listing

₹66

at current GMP

Subscribed

198.68x

overall

Open

13 Nov 2024

18 Nov 2024

Allotment

19 Nov 2024

Refund

20 Nov 2024

Demat Credit

21 Nov 2024

Listing

22 Nov 2024

Last updated 12 days ago

Overview Live GMP Subscription Status Allotment Status Filing Documents

Overall Subscription

198.68x

Total Demand

QIB Multiplier

32.49x

Institutions & Funds

NII / HNI

603.44x

High Net-Worth

Retail (RII)

119.36x

Individual Bidders

Category-Wise Subscription Breakup

Live bidding breakdown by institutional, non-institutional, and retail investors

Total 198.68x

Category	Shares Offered	Shares Applied / Bid	Times Subscribed
QIB	912,000	29,634,000	32.49x
NIB	688,000	415,166,000	603.44x
RETAIL	1,600,000	190,978,000	119.36x
Total	3,200,000	635,778,000	198.68x

Application-Wise Breakup

Total unique applications received across retail and HNI tranches

Category	Applications Reserved	Applications Received	Times Subscribed
QIB	—	22	0.00x
NIB	—	9,351	0.00x
RETAIL	—	95,489	0.00x

Day-Wise Subscription Progress

Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.

About Onyx Biotec Limited Public Issue & Market Profile

Onyx Biotec Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹29.34 Crores. The shares are offered at a price band of ₹58 to ₹61 per equity share on NSE. Currently, investors are tracking the grey market premium (GMP) and institutional subscription multiples closely across BSE and NSE portals.

Bidding & Quota Instructions:

The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.

Allotment Reconciliation Schedule:

Following the close of bidding on 2024-11-18, the basis of allotment is scheduled to be finalized on 2024-11-19. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Mas Services Limited) or the BSE allotment checking window.

Frequently Asked Questions

What is Onyx Biotec Limited IPO GMP today?

The latest Grey Market Premium (GMP) for Onyx Biotec Limited IPO is ₹5 per equity share. Based on the upper price band of ₹58 to ₹61 per equity share, the estimated listing price is ₹66 (+8.2% expected listing gain).

What is the expected profit per lot for Onyx Biotec Limited IPO?

With a lot size of 2000 shares and current GMP of ₹5, the expected profit per application lot is approx ₹10,000 (+8.2% gain). Minimum application cost is approx ₹1,22,000.

What is the issue size and price band for Onyx Biotec Limited IPO?

The Onyx Biotec Limited IPO aggregate issue size is ₹29.34 Crores with an equity price band set at ₹58 to ₹61 per equity share. The retail lot size is 2000 shares requiring a minimum capital outlay of approx. ₹1,22,000.

How can I check Onyx Biotec Limited IPO live subscription demand?

Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 198.68x (Retail: 119.36x, QIB: 32.49x, NII: 603.44x). You can track live multiples directly on our dedicated subscription page.

Where and when will Onyx Biotec Limited IPO allotment status be published?

The basis of allotment will be published on the official registrar portal (Mas Services Limited) and the BSE status verification website on or around 2024-11-19. Investors can verify status using PAN card or application number.

When is the listing date for Onyx Biotec Limited IPO?

Onyx Biotec Limited shares are scheduled to list on NSE on 2024-11-22.